Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein (ATM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04976803
Recruitment Status : Completed
First Posted : July 26, 2021
Last Update Posted : August 1, 2022
Sponsor:
Information provided by (Responsible Party):
Artios Pharma Ltd

Brief Summary:
This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Condition or disease Intervention/treatment
Solid Tumor, Unspecified, Adult Other: Determination of ATM alteration status.

Detailed Description:
The purpose of this study is to address whether ATM genomic aberrations could be used to enrich for patients with ATM LoP. Screening of unselected patient populations for ATM protein loss is likely to a lead to high failure rate by IHC testing, as the prevalence of this is expected to be low. This study could allow for identification of the types of ATM aberrations that lead to ATM LoP, and thus significantly decrease IHC failure rate by pre-selecting patients harboring such aberrations. In this study the investigator will be collecting archival tumor tissue or fresh tissue which will be assessed for ATM LoP and compared to NGS data. Additionally, patients whose tumors exhibit ATM LoP within this study could potentially enroll onto the treatment study REFMAL 721/ART0380C001.

Layout table for study information
Study Type : Observational
Actual Enrollment : 229 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Tissue Collection Study to Explore the Correlation Between ATM Genetic Alterations by Next-Generation Sequencing and ATM Loss-of-Protein Via IHC (ATR-ID Study)
Actual Study Start Date : May 28, 2021
Actual Primary Completion Date : June 30, 2022
Actual Study Completion Date : June 30, 2022

Group/Cohort Intervention/treatment
Group A
Deceased patients with archival tissue
Other: Determination of ATM alteration status.
ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Group B
Living patients with archival tissue
Other: Determination of ATM alteration status.
ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Group C
Living patients without archival tissue
Other: Determination of ATM alteration status.
ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.




Primary Outcome Measures :
  1. Number of patients with loss of ATM protein [ Time Frame: 12 months ]
    ATM protein expression levels from tumor tissue assessed by immunohistochemistry (IHC)


Secondary Outcome Measures :
  1. Number of potential patients with loss of ATM protein eligible for study REFMAL 721/ART0380C001 [ Time Frame: 12 months ]
    Patients in Group C are considered for enrolment into study REFMAL 721/ART0380C001 and must meet eligibility based on review of their medical records. REFMAL 721/ART0380C001 is a phase I/IIa open-label trial to assess the safety, tolerability, and preliminary efficacy of the ATR kinase inhibitor, ART0380 administered as a monotherapy as well as in drug combinations with gemcitabine in patients with advanced or metastatic solid tumors.

  2. Number of ATM genomic aberrations that lead to ATM LoP [ Time Frame: 12 months ]
    Identify types of ATM protein expression from tumor tissue assessed by immunohistochemistry (IHC)

  3. Rate of loss of function (LoF) of the ATM gene in patients with genomic aberrations in the ATM gene [ Time Frame: 12 months ]
    ATM alterations identified using Next-Generation Sequencing(NGS) profiles


Biospecimen Retention:   Samples With DNA
A formalin-fixed tumor tissue block or 5 freshly cut air-dried sections mounted on positively charged slides. Tissue sections cut from the blocks should be 4-5 micron thickness.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with identified ATM alterations will be potentially enrolled into this study in 1 of 3 patient populations

  • Group A: Deceased patients with archival tumor tissue
  • Group B: Living patients with archival tumor tissue
  • Group C: Living patients without archival tumor tissue
Criteria

Inclusion Criteria:

  • Patients must meet the following criteria in order to be included in the research study:

All patients (Groups A, B, and C) must meet the following criteria:

  1. Previous genetic testing of ATM genomic aberrations.
  2. ≥18 years of age.

    All living patients (Groups B and C) must also meet the additional criteria:

  3. Signed written informed consent to access archival tissue, if available.

    All Group C patients must also meet the additional criteria:

  4. Provided signed written informed consent to collect a fresh core biopsy.
  5. Have a non-irradiated, biopsiable tumor site to allow sampling for analysis via IHC for loss of ATM protein.
  6. Potentially eligible for REFMAL 721/ART0380C001:

    • Have not received a previous treatment targeting the ATR/CHK1 pathway.
    • If patients have a germline BRCA mutation or a cancer with a somatic BRCA mutation or which is HRD positive and for which there is an approved PARP inhibitor, patients should have received such treatment.
    • Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator
    • Advanced or metastatic cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study.
    • Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale

Exclusion Criteria:

There are no exclusion criteria for patients in Group A and Group B.

Group C patients who meet any of the following criteria will be excluded from study entry:

  1. Have a significant bleeding disorder or vasculitis or had a Grade 3 bleeding episode within 12 weeks prior to enrollment.
  2. Presumed ineligible for enrollment to REFMAL 721/ART0380C001:

    • Psychological, familial, sociological, or geographical conditions that that would compromise the patient's ability to adhere to future procedures likely in a Phase I protocol (such as REFMAL 721/ ART0380C001).
    • Women who are pregnant, breast feeding, or who plan to become pregnant within the next 6 months.
    • Men who plan to father a child within the next 6 months.
    • Have a serious concomitant systemic disorder that would compromise the patient's ability to adhere to a future protocol (REFMAL 721/ ART0380C001) including:

      1. One or more opportunistic HIV/AIDs-related infections within the past 12 months.
      2. Documented active or chronic infection with hepatitis B virus (positive hepatitis B surface antigen [+HBsAg]), or hepatitis C virus.
      3. Known history of clinical diagnosis of tuberculosis.
      4. Have had a malignancy prior to the current malignancy. Patients with carcinoma in situ of any origin and patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma), as judged by the medical monitor, are eligible for this study.
    • Have evidence of interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).
    • Have moderate or severe cardiovascular disease, such as the following:

      1. Have the presence of cardiac disease.
      2. Have valvulopathy that is severe, moderate, or deemed clinically significant.
      3. Have documented major electrocardiogram (ECG) abnormalities which are clinically significant.
    • Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids (patients receiving anticonvulsants are eligible).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04976803


Locations
Layout table for location information
United States, Oklahoma
Oklahoma University
Oklahoma City, Oklahoma, United States, 37104
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
United Kingdom
Sarah Cannon Research UK
London, United Kingdom, W1G6AD
Sponsors and Collaborators
Artios Pharma Ltd
Investigators
Layout table for investigator information
Study Chair: Melissa Johnson, MD Sarah Cannon Development Innovations
Layout table for additonal information
Responsible Party: Artios Pharma Ltd
ClinicalTrials.gov Identifier: NCT04976803    
Other Study ID Numbers: ART0380C002
First Posted: July 26, 2021    Key Record Dates
Last Update Posted: August 1, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Artios Pharma Ltd:
ATM
DDR
ATR
protein expression
LoF